Market Overview

Zalicus Initiates Second Phase 2a Study of Z160


Zalicus (NASDAQ: ZLCS), a biopharmaceutical company that discovers
and develops novel treatments for patients suffering from pain, today
announced that it has initiated the second of two Phase 2a clinical
studies with Z160, its first-in-class, oral, state-dependent, selective
N-type (Cav2.2) calcium channel blocker for the potential treatment of
chronic neuropathic pain. The Company also provided an overview of 2012

Z160 is designed to selectively target neuronal pain signaling by
modulating neurons that are undergoing high-frequency firing. Z160 has
demonstrated efficacy in several animal models of neuropathic pain, and
clinical trials in over 200 subjects have established Z160 as a safe and
well tolerated drug candidate.

See full press release

Posted-In: News Guidance Contracts Global


Related Articles (ZLCS)

View Comments and Join the Discussion!